Roivant Sciences Ltd. (ROIV)

Market Cap	20.23B +155.6%
Revenue (ttm)	13.31M -56.4%
Net Income	-809.24M
EPS	-1.17
Shares Out	715.70M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,325,298
Open	27.59
Previous Close	27.76
Day's Range	27.55 - 28.29
52-Week Range	8.73 - 28.28
Beta	1.23
Analysts	Strong Buy
Price Target	27.44 (-2.9%)
Earnings Date	Feb 6, 2026

About ROIV

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monocl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 750
• Stock Exchange: NASDAQ
• Ticker Symbol: ROIV
• Website: https://roivant.com

Analyst Summary

According to 8 analysts, the average rating for ROIV stock is "Strong Buy." The 12-month stock price target is $27.44, which is a decrease of -2.90% from the latest price.

Price Target

$27.44

(-2.90% downside)

Analyst Consensus: Strong Buy